Assay ID | Title | Year | Journal | Article |
AID605277 | Ratio of drug level in brain of lister rat to IC50 for PDE4 activity | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID605282 | Cognitive enhancing effect in Lister rat assessed as change in escape latency pretreated 30 mins before sample phase by water maze delayed matching to position test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID502802 | Inhibition of human PDE4C | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
| The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. |
AID314159 | Inhibition of CYP2C9 | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID314160 | Inhibition of PDE4 expressed in SF9 cells | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID388724 | Inhibition of late-phase antigen-induced bronchoconstriction in ascaris-sensitive sheep at 0.5 mg/kg, iv daily for 4 days and antigen challenged after 2 hrs post dose on 4th day | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID257464 | Cmax in rat at 20 mg/kg, po | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID257459 | Emetic threshold as plasma concentration in squirrel monkeys after 10 mg/kg oral dose | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID388720 | Bioavailability in orally and iv dosed dog | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID257447 | Inhibitory activity against PDE4B | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID388718 | Cmax in po dosed squirrel monkey assessed after first episode of emesis | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID314168 | Inhibition of ovalbumin-induced bronchoconstriction in guinea pig at 30 ug/kg, ip | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID257454 | Inhibition of early-phase antigen induced bronchoconstriction in Ascaris sensitive sheep at 0.5 mg/kg/day, iv | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID388717 | Half life in orally and iv dosed Squirrel monkey | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID447673 | Inhibition of human PDE4 | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID605284 | Drug level in brain of Lister rat during conditional taste aversion test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID605280 | Ratio IC50 for PDE4 activity in human whole blood to IC50 for PDE4 | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID605108 | Inhibition of PDE4D | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID314158 | Inhibition of LPS-stimulated TNFalpha release in squirrel monkey whole blood | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID502803 | Inhibition of human PDE4D | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
| The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. |
AID447674 | Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production treated 15 mins before LPS challenge by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID363105 | Inhibition of TNFalpha release in human whole blood | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
| Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. |
AID502804 | Ratio of IC50 for human PDE4B to IC50 for human PDE4D | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
| The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. |
AID605106 | Inhibition of PDE4A | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID388713 | Inhibition of LPS-induced TNFalpha production in Squirrel monkey whole blood | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID447849 | Therapeutic window, ratio of Cmax in squirrel monkey at 10 mg/kg to IC50 for inhibition of LPS-induced TNFalpha production in squirrel monkey whole blood | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID605275 | Drug level in brain of Lister rat during novel object recognition test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID314165 | Cmax in squirrel monkey at 10 mg/kg | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID257455 | Inhibition of late-phase antigen induced bronchoconstriction in Ascaris sensitive sheep at 0.5 mg/kg/day, iv | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID388714 | Inhibition of CYP2C9 | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID388712 | Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID388723 | Inhibition of ovalbumin-induced bronchoconstriction in conscious guinea pig at 0.03 mg/kg, ip administered 30 mins before ovalbumin challenge | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID388715 | Half life in orally and iv dosed rat | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID257446 | Inhibitory activity against PDE4A | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID447845 | Cmax in squirrel monkey at 10 mg/kg | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID605216 | Induction of adverse effect in Lister rat assessed as induction of malaise by conditional taste aversion test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID605109 | Inhibition of PDE4 activity in human whole blood assessed as inhibition of LPS-induced TNF-alpha release | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID388719 | Bioavailability in orally and iv dosed rat | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID632293 | Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells at 10 uM | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
| Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness. |
AID257467 | Inhibition of ovalbumin-induced bronchoconstriction in guinea pig at 0.03 mg/kg, ip | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID605274 | Drug level in plasma of Lister rat during novel object recognition test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID447844 | Antiinflammatory activity in squirrel monkey whole blood assessed as inhibition of LPS-induced TNFalpha production treated 15 mins before LPS challenge by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID632292 | Antitrypanosomal activity against blood stream Trypanosoma brucei brucei 427 after 48 hrs by Alamar blue assay | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
| Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness. |
AID314167 | Therapeutic index, ratio of plasma concentration causing emesis to IC50 for inhibition of LPS-stimulated TNFalpha release in squirrel monkey whole blood | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID257465 | Oral bioavailability in rat at 20 mg/kg, po | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID257466 | Tmax in rat at 20 mg/kg, po | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID605276 | Ratio of drug level in brain to plasma of Lister rat Drug level in plasma of Lister rat during novel object recognition test relative to untreated control | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID257462 | Inhibition of LPS-induced TNFalpha production in squirrel monkey whole blood | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID447676 | Clearance in iv dosed rat | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID447672 | Inhibition of human CYP2C9 | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID388711 | Inhibition of LPS-induced TNFalpha production in human whole blood | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID388710 | Intrinsic inhibition of GST-fused human PDE4A expressed in SF9 cells | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID314161 | Inhibition of LPS-stimulated TNFalpha release in human whole blood | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. |
AID447671 | Toxicity in iv dosed squirrel monkey assessed as occurrence of emesis at plasma concentration of 3.8 uM | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID502801 | Inhibition of human PDE4B | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
| The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. |
AID632291 | Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB2 expressed in baculovirus infected insect Sf21 cells | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
| Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness. |
AID388716 | Half life in orally and iv dosed dog | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID257449 | Inhibitory activity against PDE4D | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID605215 | Cognitive enhancing effect in Lister rat assessed as recognition of novel object at 0.1 mg/kg, po pretreated 90 mins before sample phase by novel object recognition test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID605278 | Ratio of drug level in plasma of lister rat during conditional taste aversion test to IC50 for PDE4 activity in rat whole blood | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID363352 | Inhibition of CYP2C9 | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
| Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. |
AID257463 | Ratio of emesis threshold plasma concentration over inhibition of LPS-induced TNFalpha production in squirrel monkey whole blood | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID363081 | Inhibition of PDE4 | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
| Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. |
AID447843 | Bronchodilator effect in guinea pig assessed as inhibition of ovalbumin-induced bronchoconstriction at 30 ug/kg, ip | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID447675 | Bioavailability in iv dosed rat | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. |
AID605283 | Drug level in plasma of Lister rat during conditional taste aversion test | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID605111 | Competitive inhibition of CYP2C9 | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID632290 | Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
| Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness. |
AID605107 | Inhibition of PDE4B | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID257450 | Inhibition of LPS-induced TNFalpha production in human whole blood | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID257448 | Inhibitory activity against PDE4C | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. |
AID388722 | Ratio of emesis Cmax in Squirrel monkey at 10 mg/kg, po to IC50 for LPS-induced TNFalpha production in Squirrel monkey whole blood | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID502800 | Inhibition of human PDE4A | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
| The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. |
AID388721 | Bioavailability in orally and iv dosed Squirrel monkey | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. |
AID605110 | Inhibition of PDE4 activity in rat whole blood assessed as inhibition of LPS-induced TNF-alpha release | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
| Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. |
AID1345239 | Human phosphodiesterase 4D (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)) | 2007 | Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
| L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. |
AID1345234 | Human phosphodiesterase 4B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)) | 2007 | Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
| L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. |
AID1345281 | Human phosphodiesterase 4C (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)) | 2007 | Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
| L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. |
AID1345251 | Human phosphodiesterase 4A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)) | 2007 | Biochemical pharmacology, Jun-15, Volume: 73, Issue:12
| L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |